



CardioTwin

An **AI-driven virtual platform** for the management of **multi-morbidities associated with cardiometabolic diseases**



CardioTwin

Framework & timeline



Today

DPA, ethics clearance and data quality and protection

2026

Model implementation, data homogenization and early use cases

2027

Virtual digital twin CardioTwin v1.0

2028

Envisioned deployment at KUH, Sweden

CardioTwin

Engagement potential

For clinical/ medical/ R&D expertise

For end users

1

Hypothesis testing and simulation

Simulate disease trajectories and treatment outcomes across patients



Co-design with healthcare providers and patients

2

Data enrichment and model training

Using XAI to enrich the Lp(a) Stockholm Study dataset and STIREG cohort (2.3M+ individuals)



Human-in-the-loop mechanisms for model fine-tuning

3

Discovery of biomarkers and pathways

Hidden associations between routine biomarkers and multi-morbidity patterns



Iterative validation in clinical settings

4

Advancing medical education

Explore patient-specific multi-morbidity scenarios, and test treatment combinations/observe outcomes in real time



Define clinical subgroups of patients based on shared features, comorbidities, and outcomes